The estimated Net Worth of David M Md Mauney is at least $272 Tysiąc dollars as of 2 January 2020. Dr Mauney owns over 22,394 units of Alaunos Therapeutics Inc stock worth over $169,892 and over the last 7 years he sold ZIOP stock worth over $101,893.
Dr has made over 2 trades of the Alaunos Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 22,394 units of ZIOP stock worth $101,893 on 2 January 2020.
The largest trade he's ever made was selling 22,394 units of Alaunos Therapeutics Inc stock on 2 January 2020 worth over $101,893. On average, Dr trades about 5,333 units every 157 days since 2017. As of 2 January 2020 he still owns at least 195,278 units of Alaunos Therapeutics Inc stock.
You can see the complete history of Dr Mauney stock trades at the bottom of the page.
Dr. David M. Mauney M.D. is the Consultant at Alaunos Therapeutics Inc.
Dr D is 52, he's been the Consultant of Alaunos Therapeutics Inc since . There are 11 older and 5 younger executives at Alaunos Therapeutics Inc. The oldest executive at Alaunos Therapeutics Inc is J. Kevin Buchi, 65, who is the Director.
David's mailing address filed with the SEC is C/O ZIOPHARM ONCOLOGY INC, ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON, MA, 02129.
Over the last 19 years, insiders at Alaunos Therapeutics Inc have traded over $2,792,771 worth of Alaunos Therapeutics Inc stock and bought 7,941,160 units worth $39,823,909 . The most active insiders traders include Randal J Kirk, Randal Jintrexon Corp Kirk oraz Lindsay A Md Rosenwald. On average, Alaunos Therapeutics Inc executives and independent directors trade stock every 72 days with the average trade being worth of $152,086. The most recent stock trade was executed by Groot Eleanor De on 22 December 2021, trading 20,132 units of ZIOP stock currently worth $25,568.
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
Alaunos Therapeutics Inc executives and other stock owners filed with the SEC include: